CTIS2023-504994-19-00
Active, not recruiting
Phase 1
A Phase II Study Evaluating the Safety and Efficacy of Glofitamab in Combination with Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients with Untreated Diffuse Large B-Cell Lymphoma - GO43075
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- F. Hoffmann-La Roche AG
- Enrollment
- 40
- Status
- Active, not recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Previously untreated patients with cluster of differential (CD20\)\-positive DLBCL, including diagnoses by the 2016 World Health Organization (WHO) classification of lymphoid neoplasms, International Prognostic Index (IPI): 1\-5, Life expectancy of \>\=6 months, Adequate biomarker blood samples prior to initiation of R\-CHOP on Day 1 of Cycle 1 and on Day 1 of Cycle 2 submitted for screening for determination of ctDNA status, At least one bi\-dimensionally fluorodeoxyglucose (FDG)\-avid measurable lymphoma lesion on positron emission tomography/computed tomography (PET/CT) scan, Left ventricular ejection fraction (LVEF) \>\=50%, as determined on cardiac multiple\-gated acquisition (MUGA) scan or cardiac echocardiogram (ECHO)
Exclusion Criteria
- •Contraindication to any of the individual components of R\-CHOP, including prior receipt of anthracyclines, history of severe allergic or anaphylactic reactions to murine monoclonal antibodies, or known sensitivity or allergy to murine products, Prior treatment for indolent lymphoma, Prior solid organ or allogeneic stem cell transplant, Positive SARS\-CoV\-2 test within 7 days prior to enrollment. Rapid antigen test result is also acceptable, Prior therapy for DLBCL and high\-grade B\-cell lymphoma (HGBCL) with the exception of palliative, short\-term treatment with corticosteroids, Pregnant or breastfeeding, or intending to become pregnant during the study or within 12 months after the final dose of R\-CHOP, 3 months after the final dose of tocilizumab (if applicable), or 2 months after the final dose of glofitamab
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 2
The Safety and Efficacy of THVD-102, a combination of Oxybutynin and Pilocarpine, in Subjects with Primary Focal Hyperhidrosis.ACTRN12615000873527TheraVida, Inc21
Active, not recruiting
Not Applicable
A Phase 2 Study Evaluating the Safety and Efficacy of ABT-751 in Combination with Docetaxel Versus Docetaxel Alone in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer - Phase 2 Study evaluating safety and efficacy of ABT-751 and Docetaxel in NSCLCEUCTR2006-002838-38-GBAbbott GmbH & Co. KG180
Active, not recruiting
Not Applicable
A Phase 2 Study to Evaluate the Safety and Efficacy of Weekly Doses of Marqibo® (vincristine sulfate liposomes injection) in Adult Patients with Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia (ALL) in Second Relapse or Adult Patients with Philadelphia Chromosome-negative ALL Who Failed Two Treatment Lines of Anti-leukemia ChemotherapyPhiladelphia Chromosome-negative Acute Lymphoblastic LeukemiaMedDRA version: 9.1Level: LLTClassification code 10000845Term: Acute lymphoblastic leukemiaEUCTR2006-006978-20-GBHana Biosciences, Inc.56
Active, not recruiting
Not Applicable
A Phase 2 Study to Evaluate the Safety and Efficacy of Weekly Doses of Marqibo® (vincristine sulfate liposomes injection) in Adult Patients with Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia (ALL) in Second Relapse or Adult Patients with Philadelphia Chromosome-negative ALL Who Failed Two Treatment Lines of Anti-leukemia ChemotherapyEUCTR2006-006978-20-DETalon Therapeutics , Inc.65
Active, not recruiting
Phase 1
A study to evaluate the safety and efficacy of Lerociclib in participants with advanced breast cancerMetastatic Breast CancerMedDRA version: 20.1Level: PTClassification code 10055113Term: Breast cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: HLTClassification code 10006289Term: Benign and malignant breast neoplasmsSystem Organ Class: 100000004872MedDRA version: 20.0Level: HLTClassification code 10006290Term: Breast and nipple neoplasms malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2021-005238-40-BEEQRx, Inc.100